Skip to main content
OpenTrials
Completed

NCT Number: NCT02750748

Pharmacokinetic Evaluation of Intranasal, Intramuscular, and Oral Naltrexone in Healthy Volunteers

To determine the pharmacokinetics of 2 intranasal doses and 1 oral dose of naltrexone compared to an intramuscular dose of naltrexone.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–55 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Vince and Associates Clinical Research, Inc.

Overland Park, Kansas, 66212, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Males and females 18 to 55 years of age, inclusive.
  • Provide written informed consent.
  • BMI ranging from 18 to 30 kg/m2, inclusive.
  • Adequate venous access.
  • No clinically significant concurrent medical conditions determined by medical history, physical examination, clinical laboratory examination, vital signs, and 12-lead ECG.
  • Male subjects must agree to use an acceptable method of contraception with female partners as well as not to donate sperm throughout the study and for 90 days after the last study drug administration. Female subject of childbearing potential must agree to use an acceptable method of birth control throughout the study and for 30 days after the last study drug administration. Oral contraceptives are prohibited.
  • Agree not to ingest alcohol, drinks containing xanthine >500 mg/day (e.g., Coca Cola®, coffee, tea, etc.), or grapefruit/grapefruit juice.
  • Participate in strenuous exercise 72 hours prior to admission through the last blood draw of the study.

Exclusion criteria

  • Please contact site for more information

Treatment and study plan

Naltrexone

Drug

Intravail

Other

Primary outcomes

  1. Plasma Concentration (Cmax)

    Time frame: 48 hours

    Measurement of serum naltrexone prior to dosing and at times 2, 3, 4, 6, 8, 12, 16, 24, 30, 36 and 48 hours after naltrexone administration

  2. Plasma Concentration (Tmax)

    Time frame: 48 hours

    Measurement of serum naltrexone prior to dosing and at times 2, 3, 4, 6, 8, 12, 16, 24, 30, 36 and 48 hours after naltrexone administration

  3. Plasma Concentration (AUC 0-t)

    Time frame: 48 hours

    Measurement of serum naltrexone prior to dosing and at times 2, 3, 4, 6, 8, 12, 16, 24, 30, 36 and 48 hours after naltrexone administration

  4. Plasma Concentration (AUC 0-inf)

    Time frame: 48 hours

    Measurement of serum naltrexone prior to dosing and at times 2, 3, 4, 6, 8, 12, 16, 24, 30, 36 and 48 hours after naltrexone administration

Secondary outcomes

  1. Adverse Events

    Time frame: Maximum of 18 days

    Will be reported from the start of the first session to follow-up visit

  2. Vital Signs

    Time frame: 12 days

    Measured before and after naltrexone administration

  3. 12-lead electrocardiogram

    Time frame: 12 days

    Measured before and after naltrexone administration

  4. Nasal Irritation Scoring

    Time frame: 5 days

    Will be reported from the start of the first session to follow-up visit

Sponsors and collaborators

Lead sponsor

National Institute on Drug Abuse (NIDA)

Nih

Registry information

Important dates

Study start
2016
Primary completion
2016
Study completion
2016
First posted
Apr 25, 2016
Registry last updated
Jan 12, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.